Stage 1: History of Subacute Respiratory Illness & Post-Antibiotic Exanthem (Timestamp: 3 Weeks Prior to Admission)
A 51-year-old male bank employee (residing in Delhi NCR, non-smoker, no alcohol/substance use, no foreign travel) presents with a 3-week history of subacute exertional dyspnea, nonproductive cough, severe fatigue, 5-kg weight loss, and a new painless exanthem following antibiotic therapy.
HPI:
- Initial Presentation: 1-week history of exertional dyspnea and cough. Treated with Doxycycline for 10 days without response.
- 3 Weeks: Progressive fatigue, anorexia, 5-kg weight loss, and left lower lobe pulmonary consolidation on chest X-ray. Treated with Azithromycin + Amoxicillin-Clavulanate with complete resolution of cough and respiratory symptoms.
- 2 Days Post-Antibiotic Completion: Developed a painless, non-pruritic maculopapular rash on face, torso, and limbs; transferred for rule-out Stevens-Johnson Syndrome (SJS). No prior medical history or drug allergies.
Hello, Chief Resident here.
Key Findings: A 51-year-old male with resolved subacute pneumonia (LLL consolidation, 5-kg weight loss) post-Azithromycin/Amoxicillin-Clavulanate, now presenting with a new post-antibiotic, painless, non-pruritic maculopapular exanthem (rule-out SJS).
Differential Diagnoses:
1. Aminopenicillin-Induced Morbilliform Exanthem (45%): Classic delayed hypersensitivity reaction appearing days after completing amoxicillin-clavulanate.
2. Post-Infectious Exanthem / Atypical Pathogen (30%): Mycoplasma pneumoniae or viral infection (EBV/CMV) causing atypical pneumonia, frequently producing rashes after aminopenicillin exposure.
3. Early DRESS / Severe Cutaneous Adverse Reaction (SJS) (15%): Antibiotic-triggered SCAR; requires vigilant monitoring for visceral involvement or mucosal sloughing.
4. Granulomatous / Endemic Disease (TB/Fungal/Sarcoid) (10%): In view of subacute course, weight loss, and Delhi NCR residence.
Recommended Prioritized Tests:
1. CBC with differential, LFTs, and RFTs: Check for eosinophilia, atypical lymphocytes, and end-organ involvement (DRESS).
2. Detailed Skin/Mucosal Exam & Biopsy: Evaluate for epidermal detachment, Nikolsky sign, or histopathology to definitively exclude SJS/DRESS.
3. High-Resolution Chest CT: Confirm resolution of LLL consolidation and assess for persistent lymphadenopathy/parenchymal disease.
4. Infectious Workup: Mycoplasma pneumoniae IgM, EBV/CMV serologies, and IGRA for Tuberculosis.
Hello Attending Consultant here
Critique: Solid prioritization of SCAR exclusion, but underweights occult malignancy/lymphoma (B-symptoms + consolidation) and over-relies on serologies without PCR/antigen. Biopsy timing suboptimal pre-steroids; omit SJS if no mucosal/Nikolsky findings.
Top 3 DDx:
1. Aminopenicillin-triggered morbilliform exanthem (post-infectious, e.g., Mycoplasma/EBV)
2. DRESS-spectrum SCAR
3. Pulmonary TB/lymphoma with paraneoplastic rash
Specific points:
1. Add peripheral smear + LDH/β2-microglobulin for occult lymphoproliferative disease.
2. Mycoplasma PCR (throat) > IgM; pair with cold agglutinins.
3. Immediate full mucosal survey + photography; defer biopsy unless progressive.
4. Quantiferon + induced sputum AFB/GeneXpert given Delhi NCR + weight loss.
5. Hold empiric steroids; serial troponin/ECG if DRESS suspected (myocarditis).
6. Re-image only if symptoms recur; baseline SpO2/ambulatory oximetry now.
7. Dermatology co-manage within 12h.
Hello, Expert Clinician here.
Best current diagnosis: A delayed morbilliform drug exanthem, most plausibly related to recent amoxicillin-clavulanate, possibly amplified by the preceding infectious illness. The antimicrobial exposure, delayed onset, diffuse maculopapular morphology, and lack of pain or blistering fit well.
Key differentials:
- DRESS: Important to exclude, but currently less likely without fever, facial edema, eosinophilia, hepatitis, nephritis, or other visceral involvement.
- SJS/TEN: Unlikely without mucosal erosions, painful dusky lesions, blistering, Nikolsky sign, or systemic toxicity.
- Infection-associated exanthem: Mycoplasma, EBV, or another viral illness can produce rash, sometimes unmasked or intensified after aminopenicillin exposure.
- TB, lymphoma, or other occult systemic disease: Weight loss warrants attention, but complete clinical resolution of the consolidation makes these less immediately compelling.
Key pivot: Mucosal integrity, fever, lesion evolution, and laboratory evidence of organ injury will separate benign exanthem from DRESS/SCAR.
Next move: Perform urgent full skin-mucosal examination with photography, plus CBC with differential, liver and renal tests; obtain dermatology review and biopsy if the eruption is atypical or progressive. Ensure radiographic resolution is documented.
Pearl: “Post-antibiotic rash” is a syndrome, not a diagnosis—mucosa, systemic toxicity, and organ laboratories define severity.
Stage 2: Physical Exam & Severe Pancytopenia with Monocytopenia (Timestamp: Admission / Day 1)
Physical Exam: Afebrile, BP 110/70 mmHg, HR 110 bpm, RR 18/min, SpO2 96% on room air. Mild pharyngeal erythema without erosions. Painless, blanching erythematous papules/plaques on face, torso, arms, and legs (palms and soles spared). Nikolsky sign negative. Abdomen: Splenomegaly (splenic edge palpable 3 cm below left costal margin).
Initial Laboratory Workup:
- Profound Pancytopenia: Total WBC 350/µL (60% neutrophils = ANC 210/µL, 37% lymphocytes, 1% monocytes = absolute monocytopenia 3.5/µL, 2% bands). Hemoglobin 10.9 g/dL (MCV 91.6 fL), Platelets 119,000/µL. Smear shows severe leukopenia with atypical lymphocytes, normal neutrophils, no blasts, no schistocytes.
- Hepatic & Inflammatory Biomarkers: AST 49 U/L, ALT 100 U/L, ALP 739 U/L, Total Bilirubin 2.1 mg/dL (Direct 1.2 mg/dL), Albumin 3.4 g/dL. Ferritin 1820 µg/L, CRP 94 mg/L. Haptoglobin, INR, and basic metabolic panel normal.
Hello, Chief Resident here.
Updated Key Findings: Profound pancytopenia (WBC 350/µL, ANC 210/µL), near-absent monocytes (3.5/µL), splenomegaly, cholestatic liver injury (ALP 739 U/L), hyperferritinemia (1820 µg/L), and non-blistering exanthem.
Differential Diagnoses:
1. Hairy Cell Leukemia (HCL) (50%): Absolute monocytopenia combined with splenomegaly, pancytopenia, and preceding opportunistic-type pneumonia is pathognomonic until proven otherwise.
2. Secondary HLH / Macrophage Activation Syndrome (25%): Suggested by marked hyperferritinemia, cytopenias, splenomegaly, and liver toxicity.
3. Disseminated Endemic Infection (e.g., Visceral Leishmaniasis, TB) (15%): Endemic exposure (Delhi NCR), splenomegaly, cytopenias, high ALP, and weight loss.
4. DRESS with Severe Hematologic Toxicity (10%): Drug-induced rash with acute liver/marrow dysfunction.
Prioritized Next Steps:
1. Bone Marrow Aspirate & Trephine Biopsy: Send for flow cytometry, BRAF V600E mutation, reticulin stain, and AFB/fungal/leish
Hello Attending Consultant here
Critique: Excellent pivot to HCL given pathognomonic monocytopenia + splenomegaly; however, under-emphasizes concurrent HLH risk (ferritin/CRP/cytopenias) and omits peripheral-blood flow as first, less-invasive step. Rash now secondary; deprioritize DRESS.
Top 3 DDx:
1. Hairy-cell leukemia (classic monocytopenia/splenomegaly/pancytopenia)
2. HCL-associated secondary HLH
3. Disseminated TB/leishmaniasis with reactive marrow suppression
Specific points:
1. Urgent peripheral-blood flow cytometry (CD20/CD103/CD25/CD11c) before marrow.
2. Add soluble IL-2R, triglycerides, fibrinogen for HLH-2004 score.
3. BRAF V600E PCR on blood/marrow; tartrate-resistant acid phosphatase stain.
4. CT abdomen to quantitate splenomegaly/lymphadenopathy; avoid contrast if renal risk.
5. Infectious: Leishmania serology/PCR, Quantiferon, blood cultures; hold empiric antimicrobials pending ANC trajectory.
6. Dermatology: punch biopsy only if rash evolves; unlikely driver.
7. Hematology consult + G-CSF if febrile; no steroids until HCL confirmed.
Hello, Expert Clinician here.
Best current diagnosis: Hairy cell leukemia, with possible secondary HLH. The combination of profound pancytopenia, near-absent monocytes, splenomegaly, and a preceding opportunistic-type respiratory illness is highly characteristic. The exanthem is now less likely to be the primary process.
Key differentials:
- Secondary HLH: Ferritin, CRP, cytopenias, and splenomegaly support this, but it may be a complication of an underlying marrow disorder rather than the root cause.
- Disseminated TB or visceral leishmaniasis: Plausible in Delhi NCR with splenomegaly, cytopenias, and cholestatic enzymes, but the extreme monocytopenia strongly favors HCL.
- DRESS: Less likely now; the rash is bland, palms/soles are spared, and the hematologic pattern is more marrow-infiltrative than drug-reactive.
Key pivot: Absolute monocytopenia plus splenomegaly redirects the case from skin/drug reaction to marrow pathology.
Next move: Urgent peripheral-blood flow cytometry and bone marrow biopsy with BRAF testing, while simultaneously checking soluble IL-2 receptor, fibrinogen, triglycerides, and leishmania/TB studies.
Pearl: In pancytopenia with splenomegaly, “missing monocytes” should immediately trigger a search for hairy cell leukemia.
Stage 3: Serologic Workup & PET-CT Imaging ("Flip-Flop Fungus Sign") (Timestamp: Hospital Days 1-2)
Diagnostic Evaluations:
- Infectious & Autoimmune Serologies: PCR negative for EBV, CMV, HHV-6, Babesia, Ehrlichia, Anaplasma, Parvovirus B19, HIV, Hepatitis A/B/C, ANA, ANCA, and respiratory virus PCR panel.
- Contrast CT & 18F-FDG PET-CT:
- Chest/Abdomen CT: 17-mm spiculated solid nodule in the left lower lobe, multistation mediastinal lymphadenopathy, and splenomegaly.
- PET-CT: Mild FDG uptake in the 17-mm left lower lobe nodule, but marked FDG hypermetabolism in supraclavicular, paratracheal, and subcarinal lymph nodes (pathognomonic "Flip-Flop Fungus Sign", where lymph nodes show greater FDG avidity than the primary pulmonary lesion, characteristic of granulomatous fungal/mycobacterial infection).
Hello, Chief Resident here.
Updated Key Findings: PET-CT demonstrates the pathognomonic "Flip-Flop Fungus Sign" (lymph node FDG uptake markedly exceeding the 17-mm LLL nodule), negative viral/autoimmune workup, and profound monocytopenic pancytopenia with splenomegaly and hyperferritinemia.
Differential Diagnoses:
1. Disseminated Endemic Fungal Infection (e.g., Histoplasmosis) +/- Underlying HCL (50%): The "flip-flop" PET sign is classic. Histoplasmosis causes profound hyperferritinemia, splenomegaly, high ALP, and marrow suppression, especially in monocytopenic host.
2. Disseminated Tuberculosis / Mycobacterial Disease (25%): Highly endemic in Delhi NCR; can replicate the "flip-flop" PET pattern, granulomatous hepatitis, and marrow suppression.
3. Primary Hairy Cell Leukemia (HCL) with Opportunistic Granulomatous Infection (15%): HCL causes pathognomonic monocytopenia, predisposing to severe fungal/TB complications.
4. Fungal/TB-Triggered Secondary HLH (10%): Explains hyperferritinemia, cytopenias, and organomegaly secondary to systemic infection.
Recommended Prioritized Tests:
1. Supraclavicular Lymph Node Biopsy: Send for GMS/PAS stains, AFB/GeneXpert, and histopathology.
2. Fungal Biomarker Panel: Urine/serum Histoplasma antigen, Beta-D-Glucan, and fungal blood cultures.
3. Bone Marrow Aspirate & Biopsy: Flow cytometry (HCL panel), BRAF V600E, and fungal/AFB cultures.
4. Induced Sputum/BAL: GeneXpert MTB/RIF and fungal cultures.
Hello Attending Consultant here
Critique: Strong recognition of flip-flop sign favoring granulomatous infection, but overweights primary histoplasmosis (rare in Delhi NCR) versus TB; under-links monocytopenia as HCL driver of opportunistic disease. Biopsy sequence correct, yet omit peripheral flow first.
Top 3 DDx:
1. HCL with opportunistic mycobacterial/fungal superinfection
2. Disseminated TB ± secondary HLH
3. Endemic mycosis (histo/crypto) unmasking occult HCL
Specific points:
1. Peripheral-blood flow cytometry (CD20/103/25/11c + BRAF) STAT before invasive biopsy.
2. Excisional supraclavicular node: AFB/GeneXpert, GMS/PAS, mycobacterial/fungal culture, flow.
3. Urine Histoplasma Ag + serum CrAg/β-D-glucan; Quantiferon + induced sputum Xpert.
4. BM aspirate/trephine concurrent: HCL panel, stains, cultures.
5. HLH markers (sIL-2R, TG, fibrinogen) to quantify cytokine storm.
6. Hold antifungals/anti-TB pending microbiology; G-CSF if febrile neutropenia.
7. Hematology-ID co-manage; avoid empiric steroids.
Hello, Expert Clinician here.
Best current diagnosis: Disseminated granulomatous infection—mycobacterial disease is now most likely, with histoplasmosis or another dimorphic fungus close behind—possibly occurring in the setting of underlying hairy cell leukemia. The disproportionately FDG-avid mediastinal/supraclavicular nodes strongly favor granulomatous infection over malignancy.
Key differentials:
- Disseminated TB: Best fits Delhi NCR, spiculated pulmonary lesion, nodal predominance, splenomegaly, and marrow suppression.
- Histoplasmosis/other endemic mycosis: Can produce the same pattern plus cytopenias, cholestatic hepatitis, and very high ferritin.
- HCL: Still crucial because profound monocytopenia is a major host clue; the infection may be opportunistic rather than primary.
- Secondary HLH: Possible unifying complication, but not the primary etiology.
Key pivot: PET-CT shifts the case from “drug rash/malignancy” to “nodal granulomatous infection in an immunologically abnormal host.”
Next move: Biopsy the most accessible hypermetabolic supraclavicular node and send tissue for histopathology, AFB/GeneXpert, GMS/PAS, fungal and mycobacterial cultures, plus flow cytometry.
Pearl: When nodes “outshine” the lung lesion on PET, think granuloma, not carcinoma.
Stage 4: Bone Marrow Core Biopsy, EBUS Lymph Node Biopsy & Genomics (Timestamp: Hospital Days 3-5)
Clinical Evolution & Diagnostic Procedures:
- On Day 3: Developed fever (38.6°C). Blood cultures, beta-D-glucan, galactomannan, and Histoplasma/Cryptococcus antigens negative. IGRA control unreactive (severe cell-mediated immune deficiency).
- Peripheral Blood Flow Cytometry: Clonal B-cell population co-expressing CD19, CD20, CD11c, CD103, and CD25.
- Bone Marrow Core Biopsy: "Dry tap" on aspiration; core biopsy showed diffuse infiltration of medium-sized lymphocytes with clear cytoplasm. Immunohistochemistry: CD20+, CD25+, CD103+, TRAP+, and Annexin A1+ — establishing Hairy-Cell Leukemia (HCL). (NGS: BRAF V600E negative).
- EBUS-Guided Mediastinal Node Biopsy: Histopathology revealed necrotizing granulomatous lymphadenitis with intracellular Acid-Fast Bacilli (AFB) on Ziehl-Neelsen stain. 16S rRNA PCR identified Mycobacterium chimaera (an opportunistic Nontuberculous Mycobacterial infection).
Hello, Chief Resident here.
Updated Key Findings: Definitive dual diagnosis established. Bone marrow core biopsy confirms Hairy Cell Leukemia (HCL) (CD20+/CD103+/CD25+/TRAP+/Annexin A1+). EBUS lymph node biopsy reveals necrotizing granulomatous lymphadenitis; 16S rRNA PCR identifies Mycobacterium chimaera. HCL-induced profound monocytopenia served as the critical risk factor for this opportunistic non-tuberculous mycobacterial (NTM) infection.
Diagnoses:
1. Hairy Cell Leukemia with opportunistic Mycobacterium chimaera infection (95%): Definitive tissue and molecular confirmation of primary malignancy and secondary NTM disease.
2. Secondary Reactive Cytokine Storm / Mild HLH Spectrum (5%): Explains hyperferritinemia and cholestasis secondary to infection plus malignancy.
Next Steps & Management:
1. Targeted Antimycobacterial Therapy: Immediately start a multi-drug regimen (Azithromycin/Clarithromycin + Ethambutol + Rifabutin).
2. Sequence HCL Direct Therapy: Temporarily delay purine analogs (Cladribine/Pentostatin) until the NTM infection is clinically controlled to avoid overwhelming immunosuppression.
3. Hematologic Support: Administer G-CSF for profound neutropenia, maintain antimicrobial prophylaxis, and monitor ferritin/liver enzymes for HLH resolution.
Hello Attending Consultant here
Critique: Accurate dual diagnosis, but underplays BRAF-negativity (favors HCL-v or IGHV4-34+ variant) and M. chimaera rarity (heater-cooler linked; confirm no cardiac hx). Delaying cladribine correct, yet regimen needs susceptibility-guided adjustment; omit HLH labeling without full criteria.
Top 3 DDx:
1. Classic HCL (Annexin+/TRAP+) with opportunistic M. chimaera
2. HCL-variant (BRAF-wt) + disseminated NTM
3. HCL + NTM-triggered secondary HLH
Specific points:
1. Repeat BRAF/MAP2K1 NGS + IGHV sequencing on marrow to subtype.
2. Start clarithromycin + ethambutol + rifabutin; add amikacin if severe; await DST.
3. Quantiferon anergy expected; serial AFB blood/node cultures for clearance.
4. Defer purine analog 4–8 wks; consider vemurafenib/rituximab bridge if BRAF+ or progressive.
5. G-CSF + PCP/MAC prophylaxis; monitor QTc/LFTs on rifabutin.
6. Ophthalmology baseline (ethambutol); echo if M. chimaera endocarditis risk.
7. ID-hematology board; PET restage at 8 wks.
Hello, Expert Clinician here.
Best current diagnosis: Hairy cell leukemia complicated by disseminated Mycobacterium chimaera infection, with the post-antibiotic exanthem and prior “pneumonia” now best understood as manifestations of profound immune dysfunction rather than a primary drug reaction.
Key differentials:
- HCL-variant: BRAF V600E negativity raises this possibility, though Annexin A1/TRAP positivity still favors classic HCL.
- Secondary HLH: Ferritin, cytopenias, fever, and splenomegaly fit partially, but the marrow and nodal findings provide a more complete explanation.
- Sarcoidosis or TB: Granulomas fit, but AFB identification and molecular speciation establish NTM disease.
Key pivot: The combination of monocytopenia, dry tap marrow, and nodal AFB transformed the case from exanthem/HLH into malignancy plus opportunistic infection.
Next move: Start culture-guided multidrug NTM therapy and urgent hematology planning to sequence definitive HCL treatment once infection control is underway.
Pearl: In HCL, the first “pneumonia” may actually be the warning shot of an opportunistic mycobacterial disease.
Stage 5: Dual Targeted Purine Analog Chemotherapy & Antimicrobial Protocol (Timestamp: Follow-up & Discharge)
Management & Long-Term Outcome:
- Final Unifying Diagnosis: Hairy-Cell Leukemia (HCL) presenting with opportunistic disseminated Mycobacterium chimaera infection.
- Targeted Treatment Plan:
- Antimycobacterial Therapy: Empirical 3-drug NTM regimen (Azithromycin + Ethambutol + Rifampin, later adjusted to Rifabutin + Clofazimine).
- Leukemia Chemotherapy: Cladribine (2-chlorodeoxyadenosine) monotherapy (Rituximab withheld due to active mycobacterial infection risk).
- Outcome: Complete abatement of fever, resolution of drug exanthem, and recovery of blood counts. Follow-up CT at 1 year showed complete resolution of the pulmonary nodule and lymphadenopathy. Patient remains in complete remission of Hairy-Cell Leukemia at 2 years.
Hello, Chief Resident here.
Key Findings: A 51-year-old male with Hairy Cell Leukemia (HCL) and disseminated Mycobacterium chimaera infection, presenting initially with subacute pneumonia, a post-antibiotic exanthem, splenomegaly, severe monocytopenic pancytopenia, hyperferritinemia, and the "Flip-Flop Fungus Sign" on PET-CT. Successfully managed with targeted antimycobacterial therapy (Azithromycin/Ethambutol/Rifabutin/Clofazimine) and Cladribine monotherapy, achieving complete hematologic and radiographic remission at 2 years.
Final Diagnoses & Probability:
1. Hairy Cell Leukemia (CD20+/CD25+/CD103+/TRAP+/Annexin A1+) with opportunistic disseminated Mycobacterium chimaera infection (95%)
2. Post-Infectious / Drug-Exacerbated Exanthem secondary to underlying immunosuppression (5%)
Key Management & Follow-up Takeaways:
1. Monocytopenia as a Diagnostic Red Flag: Absolute monocytopenia in the setting of pancytopenia and splenomegaly is highly specific for HCL and heralds severe cell-mediated immunodeficiency.
2. Infection Control Precedes Immunosuppressive Chemotherapy: Successfully clearing/controlling opportunistic NTM with targeted antimycobacterials allowed safe administration of Cladribine without precipitating fatal sepsis.
3. Long-Term Monitoring: Continue routine complete blood count surveillance, serial chest imaging, and clinical evaluation to monitor for HCL relapse or NTM reactivation.
Hello Attending Consultant here
Critique: Sound dual-therapy sequencing and outcome, but under-addresses BRAF-wt implications (possible HCL-v needing alternative agents) and clofazimine/rifabutin toxicities; rituximab deferral appropriate yet long-term MRD monitoring omitted. Exanthem correctly reclassified as secondary.
Top 3 DDx:
1. Classic HCL (Annexin A1+/TRAP+) + disseminated M. chimaera
2. BRAF-wt HCL-variant with NTM superinfection
3. Resolved secondary HLH post dual therapy
Specific points:
1. Confirm HCL subtype via MAP2K1/IGHV NGS; switch to vemurafenib-rituximab if variant/relapse.
2. Extend NTM therapy ≥12 months post-culture clearance; serial sputum/blood AFB.
3. Add MRD flow/PCR at 6/12 months; PET only if counts drop.
4. Monitor ethambutol optic neuropathy + rifabutin uveitis/QTc quarterly.
5. Lifelong CBC + monocytopenia surveillance; vaccinate post-recovery.
6. Echo/ID input for M. chimaera endovascular risk despite no prosthesis.
7. Document cladribine cumulative dose; avoid re-treatment <1 year.
Hello, Expert Clinician here.
Best current diagnosis: Hairy cell leukemia complicated by disseminated Mycobacterium chimaera infection, now in complete remission after effective sequencing of antimicrobial therapy followed by purine analog treatment.
Why it fits: HCL explains splenomegaly, pancytopenia, and especially profound monocytopenia, which created the immunologic vulnerability for disseminated NTM disease. The nodal AFB and molecular identification secure the infectious component, while marrow immunophenotyping secures HCL.
Why alternatives fall short: The exanthem was likely a secondary drug/infection-associated phenomenon, not SJS. HLH-like inflammation can mimic the presentation, but marrow and nodal pathology provide the unifying diagnosis.
Key pivot: The paired findings of dry-tap marrow with classic HCL immunophenotype and necrotizing granulomas with AFB reframed the entire illness.
Most important next move: Continue close CBC, infection, and relapse surveillance, with subtype confirmation and long-term follow-up for both HCL recurrence and NTM reactivation.
Pearl: Opportunistic NTM infection can be the presenting manifestation of occult hairy cell leukemia, and monocytopenia is the early warning clue.